Integrative Care: A Comprehensive Guide for Chronic Pain & OUD

Discover the benefits of integrative care for OUD and chronic pain models in delivering comprehensive health solutions.

Abstract: An Integrative, Evidence-Based Approach to OUD and Pain Management

This comprehensive educational post provides an in-depth exploration of modern, evidence-based treatments for opioid use disorder (OUD) and chronic pain. Writing from my perspective as a clinician with a diverse background in chiropractic, nursing, and functional medicine, I will guide you through the latest research on the pharmacology and clinical application of medications such as buprenorphine, methadone, and naltrexone. We will delve into the physiological mechanisms of these drugs, detailing how full agonists, partial agonists, and antagonists interact with the body’s mu-opioid receptors. A major focus will be on the nuances of initiating buprenorphine treatment, especially in the context of the widespread presence of illicitly manufactured fentanyl. The discussion will cover three primary initiation methods: the traditional approach, the low-dose (microdosing) approach, and the high-dose approach, analyzing the advantages and disadvantages of each.

Furthermore, this post explains how our integrative care model at Injury Medical Clinic, combining my expertise as a Doctor of Chiropractic (Dr. Jimenez) with the essential medical oversight from our Medical Director and Internist, Dr. Maria Guadalupe Cardenas, MD, can effectively manage these complex conditions. We will illustrate how chiropractic care, focused on neuromusculoskeletal health, complements medical and functional medicine protocols to provide a holistic, patient-centered treatment plan. We will also explore the use of buprenorphine for chronic pain management, harm reduction principles, and the role of adjunctive medications in supporting patients. My goal is to synthesize key research and clinical experience into an accessible, actionable guide for patients and fellow clinicians on the journey to recovery and wellness.

Introduction: A New Era in Opioid Use Disorder and Pain Treatment

Hello, I’m Dr. Alex Jimenez. With credentials spanning Doctor of Chiropractic (DC) and Advanced Practice Registered Nurse (APRN), plus multiple certifications in functional and integrative medicine (CFMP, IFMCP, ATN, CCST), my mission has always been to translate complex medical findings into accessible, actionable knowledge for my patients and the community. I believe in empowering individuals with information, drawing from the latest evidence-based research to illuminate the path toward better health. Here at Injury Medical Clinic, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, we have cultivated a unique, multidisciplinary environment dedicated to addressing complex health challenges.

A cornerstone of our practice is our collaborative structure, which is a hallmark of progressive integrative and injury care clinics. I am honored to work alongside Dr. Maria Guadalupe Cardenas, MD, our esteemed Medical Director and Collaborative Physician. Dr. Cardenas is Board Certified in Internal Medicine and brings over four decades of invaluable experience to our team. Her NPI number is 1164426749, and she is licensed in Texas under MD License #J2933. This partnership between a Doctor of Chiropractic and a Medical Doctor allows us to merge the principles of integrative health with the rigor of conventional medicine. Our team approach integrates chiropractic care, medical oversight, functional medicine, personal injury care, rehabilitation, and other specialized services to create a truly comprehensive treatment plan for each patient.

Today, I want to discuss a topic of profound importance in modern healthcare: the management of opioid use disorder (OUD) and chronic pain. The opioid crisis has been tragically reshaped by the proliferation of illicitly manufactured fentanyl, a potent synthetic opioid that presents unique challenges for both patients and clinicians. Old treatment paradigms are no longer sufficient. We must adapt, innovate, and, most importantly, listen to our patients. In this educational post, we will explore the pharmacology of medications like buprenorphine, methadone, and naltrexone, and discuss how we apply these principles within our integrated framework to support patients on their journey to recovery and wellness.

The Imperative of Medication-Assisted Treatment for Opioid Use Disorder

In my years of clinical practice, I have witnessed firsthand the devastating impact of the opioid crisis on individuals, families, and our community. As healthcare professionals, we have a responsibility to approach this challenge with compassion, evidence, and a comprehensive toolkit of effective treatments. A critical point I want to emphasize from the outset is that medication-assisted treatment (MAT) for opioid use disorder (OUD) is not merely an option; it is a life-saving, first-line intervention supported by a robust body of scientific evidence.

Why We Prioritize Medication in Treating Opioid Use Disorder

The rationale for using medications like buprenorphine and methadone is clear and compelling:

• Reduction in Mortality: The most significant benefit of MAT is its proven ability to reduce opioid-associated mortality. By stabilizing patients and reducing the risk of overdose, these medications save lives.
• Alleviation of Withdrawal and Cravings: Both methadone and buprenorphine are highly effective at managing the excruciating symptoms of acute opioid withdrawal and the persistent, overwhelming cravings that drive relapse. When these physiological drivers of addiction are controlled, individuals are given the mental and physical space to engage in recovery.
• Restoration of Life and Function: By effectively treating the neurobiological underpinnings of OUD, MAT allows patients to reclaim their lives. It empowers them to return to work, rebuild relationships, and pursue meaningful activities that contribute to their overall well-being. This is the ultimate goal of any therapeutic intervention: to restore function and quality of life.

It is also crucial to understand that substance use disorders are recognized psychiatric diagnoses. While behavioral interventions are a mainstay of comprehensive treatment, we must not gatekeep access to life-saving medical treatments. Participation in a behavioral program should not be a prerequisite for receiving evidence-based medication. People present at varying stages of readiness and ability to engage in different aspects of treatment. As effective clinicians in an integrative setting, our job is to meet people where they are, providing the level of care they are ready and willing to receive when they seek our help.

Understanding the Pharmacology: How Medications for Opioid Use Disorder Work

To appreciate why these medications are so effective, we need to dive into their pharmacology. At the heart of their mechanism is the interaction with the mu-opioid receptors in the brain. These receptors are part of our natural pain-modulating system and also influence other vital functions, including respiration. The different medications used for OUD can be categorized based on how they interact with these receptors.

Let’s visualize this relationship with a graph. Imagine the vertical y-axis represents the percentage of opioid effect, or what we call intrinsic activity, at the mu-receptor. The horizontal x-axis represents the drug dose, increasing from left to right.

The Full Agonist: Methadone

The top curve on our conceptual graph represents a full agonist, such as methadone.

• Mechanism of Action: When a full agonist binds to a mu-opioid receptor, it fully activates it, producing the maximum possible opioid effect. As the dose of methadone increases, the degree of receptor activation and the corresponding opioid effect increase in a linear fashion until a ceiling is reached where all available receptors are saturated and maximally stimulated.
• Clinical Application: This property makes methadone highly effective for treating severe withdrawal symptoms and cravings in individuals with a high tolerance to opioids. It provides a steady, long-acting opioid effect that prevents the peaks and troughs associated with short-acting opioids like heroin, thus stabilizing the patient. However, this full agonism is also what carries a significant risk of respiratory depression and overdose, especially at high doses or when combined with other central nervous system depressants. For this reason, methadone treatment is highly regulated and typically dispensed in specialized clinics.

The Partial Agonist: Buprenorphine

The middle curve on our graph represents a partial agonist: buprenorphine. This is where the pharmacology becomes particularly interesting and advantageous.

• Mechanism of Action: Like methadone, buprenorphine binds to mu-opioid receptors. However, it only partially activates them. At lower doses, increasing the dose of buprenorphine leads to an increased opioid effect. But as the dose gets higher, a “ceiling effect” is reached. The curve plateaus. Beyond this point, even if more buprenorphine is administered and binds to more receptors, it will not produce a greater opioid effect.
• The Safety Profile: This ceiling effect is a critical safety feature. The maximum opioid effect produced by buprenorphine is below the threshold that typically causes severe, life-threatening respiratory depression. This makes buprenorphine significantly safer than full agonists like methadone, heroin, or fentanyl, especially in terms of overdose risk when used alone.
• High Affinity: Another key property of buprenorphine is its high affinity for the mu-opioid receptor. This means it binds to the receptor more tightly than many full agonists. This high affinity allows it to displace other opioids (like heroin or prescription painkillers) from the receptors and then block them from reattaching. This dual action—providing enough opioid effect to prevent withdrawal and cravings while also blocking the effects of other opioids—is what makes it such a powerful tool for OUD treatment.

The Antagonist: Naltrexone

Finally, the bottom curve on our graph, hugging the x-axis, represents an opioid antagonist, such as naltrexone.

• Mechanism of Action: An antagonist binds to and occupies the mu-opioid receptors but produces zero intrinsic activity. It essentially acts as a blocker. Regardless of the dose, naltrexone will not produce any opioid effect. It binds to the receptor, preventing agonists from binding and exerting their effects.
• Clinical Application: Because it provides no opioid effect, naltrexone will not treat pain or withdrawal symptoms. In fact, if given to someone who is physically dependent on opioids, it will immediately trigger severe, precipitated withdrawal by displacing all the opioids from their receptors. Therefore, a patient must be completely opioid-free for 7-10 days before starting naltrexone. Its primary use in OUD is for relapse prevention in highly motivated individuals who have already completed detoxification. It is also important to note that because it blocks opioid receptors, it will render opioid-based pain medications ineffective, a crucial consideration for patients who may need surgery or have acute pain episodes.

The Challenge of Precipitated Withdrawal: Why We Must Proceed with Caution

Before we can discuss how to start buprenorphine, we must first understand the primary obstacle we aim to avoid: precipitated withdrawal. This concept causes a great deal of fear and apprehension among patients, and for good reason. My patients who have experienced it often describe it as “the worst withdrawal I’ve ever had,” a sentiment that underscores its severity.

What Is Precipitated Withdrawal?

Precipitated withdrawal is formally defined as the rapid and severe onset of objective signs of opioid withdrawal syndrome that occurs shortly after the administration of an opioid receptor antagonist or partial agonist, like buprenorphine. This isn’t the gradual, creeping onset of withdrawal that occurs when someone stops using opioids; this is an abrupt, intense, and often traumatic experience.

Clinically, we look for specific signs. The onset of precipitated withdrawal is typically marked by a sudden increase in the Clinical Opioid Withdrawal Scale (COWS) score by at least five points. Key physical symptoms include:

• Pupillary dilation (mydriasis)
• Piloerection (gooseflesh or “goosebumps”)
• Extreme restlessness and an inability to sit still
• Vomiting and/or diarrhea
• Yawning, rhinorrhea (runny nose), and lacrimation (teary eyes)

Beyond these physical manifestations, patients often describe an overwhelming sense of internal chaos. As I’ve observed in my practice, they may feel an uncontrollable urge to get up from the exam table, jump off, and run out of the office. They report an inability to sit still, focus, or even hold a conversation. This is more than just feeling “crummy”; it is a state of profound physiological and psychological distress.

The Neuropharmacology of Precipitated Withdrawal: A Molecular Tug-of-War

To understand why this happens, we need to look at what’s occurring at the molecular level, specifically at the mu-opioid receptors in the brain and central nervous system. These receptors are the primary targets for opioids like heroin, oxycodone, and fentanyl.

Let’s visualize this process step-by-step:

1. The State of Withdrawal (Unoccupied Receptors): Imagine the mu-opioid receptors in the brain as empty parking spots. In an individual who is dependent on opioids but has not used recently, these receptors are largely unoccupied. This lack of stimulation is what triggers the cascade of withdrawal symptoms. The body is signaling, loudly and uncomfortably, that it is missing the opioid it has become accustomed to.
2. The State of Relief (Occupied by a Full Agonist): Now, imagine that person uses a full agonist opioid, such as heroin or fentanyl. These molecules flood the system and bind to the mu-opioid receptors, fully activating them. This is like cars filling up all the parking spots and turning their engines on full blast. The result is the suppression of withdrawal symptoms and the experience of euphoria or pain relief. The person feels “well.”
3. The Precipitated Event (Buprenorphine’s Arrival): Here is where the problem arises. Buprenorphine is a partial agonist at the mu-opioid receptor, but it possesses a very high binding affinity. This means it binds to the receptor more tightly than most full agonist opioids, including heroin and morphine.

• • When a standard therapeutic dose of buprenorphine is introduced into a system where the mu-opioid receptors are already occupied by a full agonist (like fentanyl), a fierce competition ensues. Because of its high affinity, buprenorphine acts like a molecular bully. It forcefully “knocks off” or displaces the full agonist molecules from the receptors.
  • The critical issue is that while buprenorphine binds tightly, it only partially activates the receptor. It provides a “ceiling effect”: a lower level of stimulation than the full agonist it just displaced. The brain experiences a sudden and dramatic drop in overall opioid receptor activation—from a high level of stimulation (full agonist) to a much lower level (partial agonist). This abrupt transition from a state of full activation to partial activation is what precipitates the intense, rapid-onset withdrawal syndrome. It is a pharmacological shock to the system, and it is the very phenomenon we are so determined to avoid when initiating treatment.

The Fentanyl Factor: A Game-Changing Complication

The landscape of OUD treatment has been irrevocably altered by the dominance of illicitly manufactured fentanyl in the drug supply. As clinicians on the front lines, we must recognize that most patients who tell us they are buying and using opioids “off the street” are, in all likelihood, using some form of fentanyl, often without their full knowledge.

Fentanyl is not just another opioid. Its unique pharmacological properties introduce specific and formidable challenges when we try to start buprenorphine.

Lipophilicity: The Lingering Threat

One of the most significant properties of fentanyl is that it is highly lipophilic, meaning it is “fat-loving.” Unlike more water-soluble opioids like heroin or morphine, fentanyl readily dissolves in and is stored by the body’s adipose (fat) tissues.

This is critically important for two reasons:

1. Prolonged Presence: Fentanyl can remain sequestered in these fat stores for an extended period. Over time, it slowly “leaks” back out into the bloodstream, maintaining a low but persistent level of opioid agonist in the body.
2. Unpredictable Withdrawal Timeline: With heroin, a patient typically enters withdrawal within 6-12 hours of their last use. This relatively predictable timeline allowed us to use the traditional buprenorphine initiation method with some success. However, because fentanyl lingers in the body, the timeline is completely disrupted. A patient might start to feel withdrawal symptoms relatively soon after their last use. However, there may still be enough fentanyl bound to their receptors (or leaking from fat stores) to cause precipitated withdrawal if buprenorphine is started too early. We have seen cases where precipitated withdrawal occurs 48, 72, or even more hours after the last known use of fentanyl. This unpredictability makes the waiting period for traditional initiation both agonizing and risky for the patient.

Atypical Withdrawal Presentation

Another clinical observation we’ve made is that fentanyl-related withdrawal often presents differently. While classic opioid withdrawal involves a host of physical symptoms like vomiting, diarrhea, and muscle aches, patients withdrawing from fentanyl frequently report severe restlessness, profound anxiety, and dysphoria as their most prominent and distressing symptoms. These psychological symptoms can be so intense that they overshadow the more “objective” physical signs we typically measure with the COWS scale.

This atypical presentation can be misleading. A clinician might underestimate the severity of the withdrawal or even attribute the anxiety to a separate psychiatric condition, potentially delaying appropriate management. This is why listening to the patient’s subjective experience is just as, if not more, important than relying solely on a clinical scale.

Patient Experience and Treatment Hesitancy

The prevalence of fentanyl means that many of our patients have already tried to start buprenorphine on their own or in other clinical settings. Many have had negative experiences, including suffering through precipitated withdrawal. This trauma can lead to very strong and valid opinions about treatment. They may be fearful, skeptical, and hesitant to try again.

As I emphasize in my conversations with patients at our clinic, their past experiences are a vital part of their story. We must acknowledge their fears and engage in a transparent, collaborative dialogue. This principle of shared decision-making is not just a nicety; it is the cornerstone of effective and compassionate care in this new era.

A Closer Look at Buprenorphine: Formulations and Indications

Given its unique profile as a partial agonist, buprenorphine has become a cornerstone of both OUD treatment and, in some formulations, chronic pain management. Understanding the different products available is essential, as their composition and approved indications vary significantly.

Buprenorphine-Only (Mono-Product) Formulations

These products contain only buprenorphine as the active ingredient.

• Subutex: This is a sublingual tablet form of buprenorphine approved for the treatment of opioid use disorder. It was one of the first buprenorphine products to become widely available.
• Butrans Patch: This transdermal patch delivers a continuous, low dose of buprenorphine over seven days. It is FDA-approved specifically for the management of moderate to severe chronic pain that requires around-the-clock, long-term opioid treatment. Its low, steady delivery is not suitable for treating OUD.
• Brixadi: This is an extended-release injectable formulation of buprenorphine. It comes in both weekly and monthly versions and is approved for moderate to severe OUD. There is also a buccal formulation of a similar product (Belbuca) approved only for chronic pain.
• Buprenex: This is an injectable form of buprenorphine typically used in controlled medical settings for the management of acute pain, such as post-operative pain.

Buprenorphine with Naloxone (Combination Products)

These products combine buprenorphine with the opioid antagonist naloxone. The most common brand names are Suboxone and Zubsolv, which come in sublingual film or tablet forms and are approved for opioid use disorder.

• The Role of Naloxone: The naloxone in these combination products is there as a diversion and misuse deterrent. When the film or tablet is taken sublingually as prescribed, the buprenorphine is readily absorbed through the mucous membranes under the tongue, but the naloxone is not. It has very poor sublingual bioavailability and is largely swallowed and metabolized by the liver, so it has no significant effect.
• Deterring Injection: However, if an individual attempts to misuse the medication by crushing and injecting it, the naloxone becomes fully bioavailable. As an antagonist, it will immediately block the mu-opioid receptors, overpowering the partial agonist effect of the buprenorphine and inducing immediate, severe precipitated withdrawal. This unpleasant experience is a powerful deterrent against intravenous misuse.
• Potential Side Effects: In my clinical experience, a small subset of patients report side effects like headaches or gastrointestinal upset even when taking the combination product correctly. This may be due to the small amount of naloxone that is absorbed or other formulation ingredients. In such cases, I have a very low threshold for switching the patient to a buprenorphine-only (mono) product like Subutex. However, some insurance plans may have stricter criteria for covering the mono-product, and some providers may be hesitant to prescribe it because of historical concerns about diversion. As a provider, I always ensure a patient has a clear and continuous care plan, whether they are on a mono-product or a combination product.

Charting the Indications: A Clear Guide

Indication	Approved Buprenorphine Formulations
Opioid Use Disorder (OUD) & Withdrawal	Subutex (sublingual tablet), Suboxone/Zubsolv (sublingual film/tablet), Sublocade (monthly injection), Brixadi (weekly/monthly injection)
Chronic Pain	Butrans (transdermal patch), Belbuca (buccal film)
Acute Pain	Buprenex (injectable, in-hospital)
Off-Label Use for Chronic Pain	Subutex and Suboxone are frequently used off-label for complex chronic pain, particularly in patients with a history of OUD or complex persistent opioid dependence.

Initiating Buprenorphine for Opioid Use Disorder: A Step-by-Step Guide

Starting a patient on buprenorphine is a precise clinical process that requires careful planning and patient education to be successful and safe. The goal is to transition the patient from a short-acting opioid to buprenorphine without inducing precipitated withdrawal.

Pre-Initiation Counseling and Shared Decision-Making

Before giving the first dose, a thorough and transparent conversation must take place. This is a cornerstone of my practice and embodies the principle of shared decision-making.

1. Confirm the Diagnosis: First, I ensure the patient meets the clinical criteria for at least a moderate to severe opioid use disorder. This is a serious diagnosis, and buprenorphine is a long-term commitment.
2. Informed Consent: I engage in a detailed informed consent discussion. Key points include:

• • Nature of Buprenorphine: I explain clearly that buprenorphine is itself a form of opioid and that they will become physically dependent on it. This is not the same as addiction (which involves compulsive, harmful use), but it means their body will adapt to the medication. They will experience withdrawal if it is stopped abruptly.
  • The Challenge of Discontinuation: I am transparent about the fact that tapering off buprenorphine can be a long and challenging process. This is a long-term treatment, not a short-term fix.
  • Alternatives: We discuss alternatives, especially if the OUD is mild or the clinical picture is more dominated by chronic pain where other non-opioid treatments have not been fully explored.

• Crucial Counseling Points:

• • The Risk of Precipitated Withdrawal: This is the most critical point. I explain that buprenorphine must only be started when they are in a state of mild to moderate withdrawal. If taken too soon, the high-affinity buprenorphine will “rip” the full-agonist opioids off their receptors and trigger immediate, intense withdrawal symptoms. We will discuss the timing in detail.
  • Proper Administration: I physically demonstrate how to take the sublingual medication. The film or tablet must be placed under the tongue and allowed to dissolve completely for at least 10-15 minutes. I advise them not to talk, eat, or drink during this time. For patients who experience nausea, I suggest they spit out the accumulated saliva after the medication has dissolved, as absorption occurs through the oral mucosa, not the stomach.
  • Dental Health: I discuss the potential risk of dental side effects, such as caries or decay, reported in case studies. I emphasize that this risk can be significantly mitigated by practicing good oral hygiene—brushing teeth after the medication has dissolved and maintaining regular dental check-ups.
  • Safety with Other Substances: I strongly warn against the risk of combining buprenorphine with other central nervous system depressants, particularly alcohol and benzodiazepines. While buprenorphine alone has a high safety ceiling for respiratory depression, this safety is compromised when combined with other depressants, and the risk of a fatal overdose increases significantly.

Patient Selection and Considerations

While buprenorphine is safe for most patients, some require special consideration. In individuals with severe liver impairment or acutely elevated liver enzymes (transaminitis), caution is warranted. The liver metabolizes Buprenorphine, and impaired function can lead to higher-than-expected drug levels, increasing the risk of sedation and respiratory depression. In these cases, we would start with a lower dose and monitor liver function tests closely.

After this comprehensive discussion, if the patient and I agree to proceed, we lay out a clear plan for the initiation, also known as an “induction.”

Navigating Buprenorphine Initiation: Three Modern Approaches

Given the challenges posed by fentanyl and the paramount need to avoid precipitated withdrawal, the clinical community has moved beyond a one-size-fits-all model. We now have several strategies at our disposal, each with its own protocol, risks, and benefits. The choice of method is not arbitrary; it is a carefully considered decision made in partnership with the patient.

I am going to discuss three primary approaches for starting buprenorphine:

1. The Traditional Approach
2. The Low-Dose (Microdosing) Approach
3. The High-Dose Approach

These methods differ in three key aspects:

• Initial Starting Dose of Buprenorphine: How much medication is given at the beginning.
• Required Time Since Last Use: The “washout” period of abstinence from full agonist opioids.
• Extent of Withdrawal at Start: How sick the patient needs to be before the first dose.

The following table provides a brief overview, which we will explore in much greater detail.

Initiation Method	Time Since Last Fentanyl Use	Required Withdrawal State	Initial Buprenorphine Dose
Traditional Approach	At least 48-72 hours	Mild to Moderate (COWS 8-12+)	2-4 mg
Low-Dose Approach	0 hours (concurrent use)	No withdrawal required	0.25-0.5 mg
High-Dose Approach	At least 12-24 hours	Moderate to Severe (COWS 13+)	8-16 mg
It is essential to note that while the traditional method was the original standard of care and the focus of early research, it is no longer the preferred or go-to method for most patients using illicit fentanyl. The risk of precipitated withdrawal is too high. Instead, we are increasingly utilizing the low-dose and high-dose methods, which were specifically developed to navigate the complexities of fentanyl.

The Power of Shared Decision-Making: A Patient-Centered Philosophy

At this point, the research has not definitively proven one initiation method to be universally superior for all patients using fentanyl. The “best” method is often the one that aligns with the individual patient’s physiology, past experiences, priorities, and the clinical setting in which care is being delivered. This is where shared decision-making becomes paramount.

ASAM Guidance and the Importance of Individualization

The American Society of Addiction Medicine (ASAM) released a helpful clinical considerations document in 2023 that echoes this philosophy. It underscores that buprenorphine initiation is best individualized based on the setting and, crucially, patient preference (American Society of Addiction Medicine, 2023). This departs from a rigid, prescriptive model and moves toward a more flexible, collaborative one.

Our own team at Injury Medical Clinic, working with collaborators like those at Oregon Health and Science University, strongly advocates for this approach. Through qualitative research and clinical experience, we’ve learned that patients are the true authorities on their own bodies and experiences. When we empower them with clear information about their options, they can tell us what they prioritize.

What Matters to Patients? Insights from Qualitative Research

Recent qualitative studies have provided powerful insights into patients’ perspectives (King, R. S., et al., 2023). Thematic analysis of patient interviews reveals several key themes:

• Autonomy and Individualization: Patients deeply value control and a treatment plan tailored to them. One patient in a study eloquently stated, “My doctor, she told me, do what I feel comfortable doing. And that was so nice.” This simple statement captures the profound impact of empowering a patient with information and choice.
• Prioritizing a Painless Transition: For many, the single most important goal is to avoid withdrawal symptoms altogether. Another patient expressed, “For me, I just did not want to have to deal with the pain at all.” For a patient with this priority, a low-dose initiation, which is designed to prevent withdrawal, may be the most appealing and appropriate option.
• Setting Realistic Expectations: Patients also provided critical feedback for clinicians. They emphasized the need to describe withdrawal accurately. One patient noted, “When you have the flu, you don’t have this crushing anxiety and depression and hopelessness.” This highlights the severe mental and emotional components of withdrawal, especially from fentanyl, which are often understated by the term “flu-like symptoms.” As clinicians, we must be honest and comprehensive in our descriptions to build trust and prepare patients for the journey ahead.

Clinical Tools for Assessment and Management

To guide our initiation protocols, we rely on a combination of objective measurement and subjective patient reporting, along with a toolbox of medications to manage specific symptoms.

The Clinical Opioid Withdrawal Scale (COWS)

The COWS is an 11-item, clinician-administered scale that helps us quantify the severity of opioid withdrawal. It assesses a range of objective and subjective signs, including:

• Resting pulse rate
• Sweating
• Restlessness
• Pupil size
• Bone or joint aches
• Runny nose or tearing
• GI upset
• Tremor
• Yawning
• Anxiety or irritability
• Gooseflesh skin

Each item is scored, and the total score categorizes withdrawal as mild (5-12), moderate (13-24), moderately severe (25-36), or severe (>36).

While the COWS is an essential tool, particularly for the traditional and high-dose methods, I must stress that it is only one piece of the puzzle. We must always listen to the patient. Given the propensity for fentanyl-related withdrawal to manifest primarily as severe anxiety and restlessness before other objective signs appear, a patient’s self-report of distress is a critical data point that should never be dismissed, even if their COWS score is not yet in the moderate range.

Adjunct Medications: A Symptom-Targeted Approach

A crucial part of any buprenorphine initiation is providing robust support for the withdrawal symptoms that may arise. This is what we call symptom-targeted treatment. My approach is always to discuss with the patient what their most bothersome symptoms are and what has worked for them in the past. It is another opportunity for shared decision-making.

If there are no contraindications and under Dr. Cardenas’s medical supervision, our team often provides patients with a “comfort medication” kit. This typically includes prescriptions for:

• Clonidine: An alpha-2 adrenergic agonist that is excellent for managing the autonomic hyperactivity of withdrawal, such as restlessness, anxiety, sweating, and tremors.
• Tizanidine: A muscle relaxant that can be very effective for the intense muscle cramps and all-over body aches of withdrawal.
• Hydroxyzine: An antihistamine with sedative and anxiolytic properties, useful for anxiety, restlessness, and insomnia.
• Trazodone: A sedating antidepressant, often used at low doses to help with the profound insomnia that accompanies withdrawal.
• NSAIDs (like Ibuprofen) or Acetaminophen: For generalized pain and body aches.
• Ondansetron (Zofran): A potent antiemetic for managing nausea and vomiting.
• Loperamide (Imodium): For controlling diarrhea, though we use it cautiously and with clear instructions to avoid high doses.

Providing these medications proactively shows the patient we are committed to their comfort and gives them a sense of control over their symptoms.

In-Depth Analysis of Buprenorphine Initiation Methods

Now, let’s take a deep dive into the specifics of each of the three initiation methods, exploring the protocols, the rationale, and the clinical considerations for each.

1. The Traditional Initiation Method

The traditional approach is the classic method that was developed and studied when buprenorphine first became available for office-based OUD treatment. It is based on a simple principle: wait until the full agonist opioid is sufficiently cleared from the body and the patient is in a clear state of withdrawal before starting a low dose of buprenorphine.

Protocol

• Patient Population: This method is now considered most appropriate only for someone switching from short-acting full agonist opioids like heroin or oxycodone to buprenorphine. As I have emphasized, we rarely use this approach anymore for patients using illicit fentanyl.
• Abstinence Period: The patient must abstain from all full agonist opioids for a specific period to allow the drug to wash out of their system.

• • Short-acting opioids (e.g., oxycodone, heroin): 12 to 24 hours.
  • Long-acting opioids (e.g., extended-release morphine, methadone): 24 to 72 hours.
  • Fentanyl: At least 48- 72 hours, and even this is often insufficient and highly risky. The difficulty for a fentanyl-dependent individual to abstain for this long without experiencing severe, unmanageable withdrawal is a major barrier.

• Initiation Criteria: The patient must be in at least mild to moderate withdrawal, typically corresponding to a COWS score of 8-12 or higher. The more severe the withdrawal, the greater the relief the patient will experience from the first dose of buprenorphine.
• Dosing:

• • Day 1: Start with an initial dose of 2 mg to 4 mg of buprenorphine.
  • Observe the patient for 1-2 hours. If withdrawal symptoms improve or stay the same, it is safe to proceed. If they worsen, it is a sign of precipitated withdrawal, and the initiation must be stopped.
  • If the first dose is tolerated, repeat with small doses (e.g., 2-4 mg) every 2-4 hours, titrating up to a total maximum dose of 16 mg to 24 mg on the first day. The goal is to make the patient comfortable.

Advantages of the Traditional Method

• Familiar and Well-Studied: This is the approach most clinicians were originally trained on, and it has a long history of research behind it (primarily in the pre-fentanyl era).
• Simple Dosing: It does not require cutting or splitting tablets or films, as the starting dose of 2 mg is the lowest standard formulation available.
• Less Intensive Follow-up: Compared to the low-dose method, it generally requires less frequent check-ins and care coordination once the patient is stabilized.

Disadvantages of the Traditional Method

• High Risk of Precipitated Withdrawal with Fentanyl: This is the most significant and often prohibitive disadvantage. Due to fentanyl’s lipophilicity and long, unpredictable half-life, a patient can be in moderate withdrawal and still have enough fentanyl on their receptors to trigger a severe precipitated event.
• Insufficient Starting Dose: For individuals with a high tolerance from daily fentanyl use, an initial dose of 2-4 mg of buprenorphine is often like “throwing a glass of water on a house fire.” It is simply not enough to provide relief from their withdrawal, leading to a frustrating and uncomfortable experience even if precipitated withdrawal is avoided.
• The Agony of the Waiting Period: Requiring a person who uses fentanyl to wait 48-72 hours is often an insurmountable barrier. The withdrawal they experience during this time can be so severe that it leads them to give up on the initiation attempt and return to use to find relief. This period without effective pain management or withdrawal management is a major failing of this approach in the current context.

2. The Low-Dose Initiation Method (Microdosing)

Low-dose initiation, often called “microdosing” or the “Bernese method,” is a revolutionary approach designed to solve the primary problem of the traditional method: it takes withdrawal completely out of the equation.

The Core Premise: A Gradual Crossover

The fundamental principle of a low-dose initiation is to gradually introduce buprenorphine onto the opioid receptors by starting at an extremely low (sub-therapeutic) dose and slowly titrating upwards over several days. Crucially, this is done while the person is still using their full agonist opioid of choice (e.g., illicit fentanyl, methadone, or prescription opioids).

By introducing tiny amounts of buprenorphine, we allow it to slowly and gently begin occupying the mu-opioid receptors without causing a sudden, massive displacement of the full agonist. Over several days, the buprenorphine concentration at the receptor level gradually accumulates. The patient remains comfortable throughout this process because the full agonist is still present to prevent withdrawal.

Eventually, enough receptors become occupied by buprenorphine to reach a therapeutic level. At this point, the full agonist can be safely stopped completely, and the patient seamlessly transitions to a full maintenance dose of buprenorphine. This process avoids withdrawal altogether.

This method is based on the explicit understanding that opioid-dependent people will be using full agonist opioids to manage their underlying dependence during the buprenorphine titration period.

Visualizing the Low-Dose Process

Let’s return to our molecular visualization:

• Instead of introducing a large dose of buprenorphine all at once (the traditional method’s risk), we introduce just a few molecules of buprenorphine (the “microdose”).
• These few molecules find a few unoccupied receptors or gently displace a few full agonist molecules. Still, the change in overall receptor activation is so small that it is imperceptible to the patient. They feel no change, and certainly no withdrawal.
• Day after day, as we slowly increase the dose, more and more buprenorphine molecules accumulate on the receptors. The proportion of receptors occupied by buprenorphine steadily increases, while the proportion occupied by the full agonist decreases.
• The result is a gradual, gentle “crossover” at the receptor level. By the time the patient stops the full agonist, buprenorphine is already the dominant molecule, and the transition is smooth and comfortable.

Example Low-Dose Initiation Schedules

Low-dose initiation dosing is highly situation-specific and can be adjusted as the patient tolerates titration. There is no single “correct” schedule, but here are two common examples used in the ambulatory (outpatient) setting.

1. Faster (4-Day) Ambulatory Schedule: This is generally the fastest we would attempt a low-dose start in an outpatient clinic.

Day	Morning Dose (Buprenorphine)	Evening Dose (Buprenorphine)	Total Daily Dose	Instructions for Full Agonist Use
1	0.5 mg	0.5 mg	1 mg	Continue usual full agonist use.
2	1 mg	1 mg	2 mg	Continue usual full agonist use.
3	2 mg	2 mg	4 mg	Continue usual full agonist use. This is the last day.
4	4 mg	4 mg	8 mg	STOP all full agonist use. May take more buprenorphine as needed for withdrawal.
5+	Increase buprenorphine to a stable maintenance dose (typically 12-24 mg daily).
B. Slower (7-Day) Ambulatory Schedule: Some patients prefer a slower, more gradual approach, especially if they have had negative experiences in the past or are particularly anxious about the process.
Day	Total Daily Buprenorphine Dose	Instructions for Full Agonist Use
—	—	—
1	0.5 mg	Continue usual full agonist use.
2	1 mg	Continue usual full agonist use.
3	2 mg	Continue usual full agonist use.
4	4 mg	Continue usual full agonist use.
5	8 mg	Continue usual full agonist use.
6	12 mg	STOP all full agonist use.
7	16 mg+	Titrate to a stable maintenance dose.
Important Clinical Considerations for Low-Dose Starts:

• Harm Reduction Counseling: Since we are explicitly assuming the patient will continue to use illicit opioids for the first several days, thorough education on overdose prevention and harm reduction is non-negotiable. We must discuss having naloxone available, never using alone, and using “tester shots” to gauge potency.
• Protection from Overdose: It is vital to explain to the patient that buprenorphine is not protective against overdose until it reaches a daily dose of around 8 mg. This means that during the first few days of the titration, they are still at high risk of overdose from their illicit fentanyl use. This protective effect only kicks in toward the end of the initiation schedule.
• Hospital vs. Outpatient Setting: In a controlled hospital setting, we can provide prescribed full agonists like methadone or oxycodone during the crossover period. In the outpatient setting, this is not feasible, so we must work within the reality of a patient’s continued illicit use.

Advantages of the Low-Dose Initiation

• Patient Preference: Many patients strongly prefer this method because it promises a transition with minimal to no withdrawal symptoms. It directly addresses their primary fear.
• Reduced Risk of Precipitated Withdrawal: When done correctly, the risk of precipitated withdrawal is significantly lower than with the traditional method.
• Excellent for Pain Management Needs: This is a critically important advantage. Many of our patients suffer from concurrent acute or chronic pain. The low-dose method allows them to continue their full agonist pain medication while simultaneously being inducted onto buprenorphine for OUD. This makes it possible to treat both conditions without forcing the patient to endure a period of untreated pain.

Disadvantages of the Low-Dose Initiation

• Complex Regimen: This is a significant practical challenge. The starting doses (0.25 mg, 0.5 mg) are much smaller than the smallest available buprenorphine formulation (2 mg film/tablet). This requires us to give patients detailed instructions on how to cut the films or dissolve tablets in water to measure out the tiny doses. This can be confusing and lead to errors.
• Need for Continued Opioid Agonists: As discussed, this method relies on the patient having access to and using full agonists to manage withdrawal along the way, which carries inherent risks in an outpatient setting.
• Difficulty Adhering to a “Quit Date”: I have found in my clinical practice that some patients struggle with the crossover nature of this method. Having to consciously stop using their full agonist on Day 4 or Day 6 can be psychologically challenging. They may be tempted to “dabble” or continue using both substances, which can make it harder to discontinue the illicit use and stabilize on buprenorphine fully.
• High Need for Care Coordination: This method is not “set it and forget it.” It requires frequent communication between the patient and the clinical team. In our clinic, patients undergoing a low-dose start often call us daily or every other day with questions about dosing, symptoms, or what to expect next. We must have the infrastructure to support this level of engagement.
• Questionable Success Rate in Outpatient Settings: This is a sobering but important point. While the theory is sound, real-world application can be difficult. A recent retrospective cohort study found a success rate of only 34% for low-dose initiations in a low-barrier outpatient setting (Priest, K. C., & Korthuis, P. T., 2023). This suggests that while it works well for some, many challenges and barriers can hinder successful completion outside a controlled hospital environment.

Despite these challenges, the low-dose method remains a vital tool in our arsenal, especially for patients who prioritize avoiding withdrawal above all else. Success hinges on a strong patient-clinician relationship, clear education, and robust support.

3. The High-Dose Initiation Method

The high-dose initiation method, sometimes called “rapid induction” and pioneered by programs like California Bridge, represents a third, distinct philosophy. Instead of waiting a long time (traditional) or avoiding withdrawal entirely (low-dose), this method involves waiting a shorter period, allowing the patient to enter more significant withdrawal, and then administering a large, robust dose of buprenorphine to saturate the receptors and provide relief rapidly.

The Rationale: Overcoming Fentanyl with a Macrodose

The thinking behind this approach is that the low starting dose of the traditional method (2-4 mg) is insufficient to compete with the fentanyl still present in a patient’s system. By waiting until the patient is in significant withdrawal (indicating that many receptors are already empty) and then giving a large “macrodose” of buprenorphine (e.g., 8-16 mg), we can quickly overcome any remaining fentanyl, fully occupy the receptors with buprenorphine, and rapidly alleviate the withdrawal state.

This method is most often used in urgent care or emergency department (ED) settings, where a patient can be observed for a period after the large initial dose. However, with careful patient selection and education, it is increasingly being used in ambulatory settings as well.

Protocol

• Abstinence Period: The patient must have abstained from use for a shorter, more manageable period.

• Fentanyl: At least 12 hours, though some protocols push this to 18-24 hours for safety. This is a much more achievable goal for most patients than the 48-72 hours of the traditional method.

• Initiation Criteria: This is the key difference. The patient must be in moderate to severe withdrawal.

• • COWS Score: A COWS score of greater than 13 is typically required.
  • Objective Signs: We also look for at least two objective signs of opioid withdrawal, such as visibly dilated pupils, palpable piloerection (gooseflesh), a runny nose, or observable restlessness. This ensures we are not just relying on the patient’s subjective report of anxiety.

• Dosing:

• • Once the patient meets these criteria, you administer a single, hefty dose of buprenorphine. For patients using fentanyl, we are now more often using 16 mg as the initial dose. For other opioids, 8 mg may be sufficient.
  • You then observe the patient in the clinic or ED for at least 30-60 minutes. This observation period is critical to assess how they tolerated the large first dose and to ensure precipitated withdrawal does not occur.
  • If the initial dose is tolerated and symptoms improve, the patient can be discharged. An additional 8 mg dose may be given as needed for breakthrough symptoms, up to a total of 32 mg on the first day.
  • Day 2 and beyond: The patient continues a high maintenance dose, typically in the range of 24 mg to 32 mg per day for fentanyl users. We are increasingly recognizing that patients using high-potency synthetic opioids may need daily doses greater than the previously standard 16- 24 mg for full stabilization and craving control.

Advantages of the High-Dose Initiation

• Rapid Transition: The entire initiation process can be completed in a single clinic visit, which is highly efficient.
• Simple Dosing: No complex calculations or tablet/film cutting is needed. The patient starts on a standard, large dose.
• Simple Process: The protocol is straightforward for most patients to understand without extensive coaching.
• Effectiveness in Acute Care Settings: It is an ideal protocol for the ED or urgent care, allowing clinicians to stabilize a patient in crisis and connect them to ongoing outpatient care. Its use is also growing in ambulatory clinics that have the capacity for a short observation period.

Disadvantages of the High-Dose Initiation

• Severity of Precipitated Withdrawal: This is the primary risk. If precipitated withdrawal occurs with this method, it is likely to be severe because a very large dose of buprenorphine was administered. The patient must be fully and transparently informed of this risk.
• Requires Significant Withdrawal: The patient must be willing and able to tolerate moderate-to-severe withdrawal before treatment can begin. While the waiting period is shorter, the sickness is more intense.
• Requires Observation: The need for a post-dose observation period can be a logistical challenge for outpatient clinics not set up for it.

A New Horizon in Chronic Pain Management: The Role of Buprenorphine

For decades, the standard of care for moderate to severe chronic pain often involved the use of full-agonist opioids like oxycodone, hydrocodone, or morphine. While effective for acute pain, their long-term use is fraught with challenges, including escalating tolerance, a high risk of dependence, and a host of debilitating side effects. As clinicians, we have been seeking safer, more sustainable alternatives. This is where buprenorphine emerges as a game-changing option for pain management.

Unveiling Buprenorphine: A Unique Approach to Pain Relief

As we’ve discussed, buprenorphine is classified as a partial mu-opioid receptor agonist with a “ceiling effect.” This key safety profile means it provides substantial pain relief (analgesia) but has a maximum limit on its effects, most importantly on respiratory depression—the primary cause of fatal opioid overdoses.

Beyond the Mu-Receptor: The Multifaceted Action of Buprenorphine

Buprenorphine’s unique pharmacology doesn’t stop there. It also interacts with other opioid receptors, which contributes to its favorable properties:

• Kappa Opioid Receptor Antagonist: Buprenorphine acts as an antagonist at the kappa opioid receptor. Activation of the kappa receptor is associated with negative feelings like dysphoria (a state of unease or dissatisfaction), stress, and anxiety. By blocking this receptor, buprenorphine may help improve mood and reduce the aversive psychological symptoms that can accompany chronic pain and opioid use. In my clinical practice, I have certainly witnessed patients report a notable reduction in depressive symptoms and an overall improvement in their sense of well-being after transitioning to buprenorphine.
• Delta Opioid Receptor Activity: It also has activity at the delta opioid receptor, which may contribute further to its analgesic effects.

The Clinical Advantages of Buprenorphine Over Traditional Opioids

These pharmacological actions translate into a multitude of clinical benefits that I consistently observe and that a growing body of research supports.

• Reduced Risk of Hyperalgesia: A cruel irony of long-term full-agonist opioid use is a phenomenon called opioid-induced hyperalgesia, where the nervous system becomes sensitized, and the patient paradoxically becomes more sensitive to pain. Buprenorphine is significantly less likely to induce this condition, making it a more stable long-term solution.
• Potential for Improved Mood: As mentioned, its action as a kappa antagonist may contribute to reduced depression. This is a profound benefit for patients with chronic pain, a condition that is very often comorbid with mood disorders.
• Less Sedation: Patients on buprenorphine generally report feeling less sedated and more clear-headed compared to when they were on full-agonist opioids. This allows them to be more engaged in their daily lives, work, and, importantly, their physical rehabilitation programs.
• Lower Likelihood of Physical Dependence and Milder Withdrawal: While physical dependence does occur with buprenorphine (as it does with any opioid taken long-term), the degree of dependence is often less severe. When the medication is discontinued, the resulting withdrawal syndrome is generally reported to be milder and more manageable compared to the abrupt cessation of full agonists.
• Favorable Side Effect Profile: Buprenorphine has a lower incidence of many of the classic opioid-related side effects.
• Reduced Association with Long-Term Opioid Risks: It is not associated with some of the more insidious risks linked to chronic full-agonist opioid therapy, including:

• • Falls: Due to less sedation and cognitive impairment.
  • Hypogonadism: A common issue with long-term opioids that leads to low testosterone in men and hormonal imbalances in women.
  • Immunosuppression: Full agonists can suppress the immune system, leaving patients more vulnerable to infections.
  • Cognitive Impairment: Patients on buprenorphine often feel “less foggy” and more mentally sharp.

All of these factors combine to make buprenorphine a truly compelling and superior option for providing long-term analgesia in many patients with chronic pain. It offers a pathway to effective pain management with a significantly enhanced safety margin.

Selecting the Right Candidates for Buprenorphine Therapy for Pain

Transitioning a patient to buprenorphine for pain is a clinical decision that requires careful consideration. It is not a first-line therapy for all pain, but rather a powerful tool for a specific patient population. Here is the process we follow at our clinic.

Step 1: Rule Out Active Opioid Use Disorder (OUD)

The first and most critical step is to perform a thorough assessment to rule out a current, active Opioid Use Disorder (OUD). This can be a nuanced evaluation. The key distinction often lies in the pattern of use. Are they using the medication as prescribed for pain relief, or is there a pattern of compulsive use, loss of control, and use despite harm? If OUD is present, they would be started on a higher-dose, sublingual formulation of buprenorphine (e.g., Suboxone) specifically for OUD treatment, which is a different clinical pathway than using buprenorphine for chronic pain alone.

Step 2: Exhaust Less Risky, Non-Opioid Options

Before we consider an opioid of any kind, we ensure that we have exhausted all appropriate non-opioid and less risky treatment modalities. This is the foundation of our integrative care model and includes:

• Chiropractic Care & Physical Rehabilitation
• Functional Medicine & Nutrition
• Non-Opioid Pharmacological Agents
• Mind-Body Therapies
• Interventional Procedures

Only when a patient has genuinely engaged with and failed to achieve adequate pain relief from a robust, multimodal, non-opioid plan do we then consider moving to the next level of care.

Step 3: Identify Patient Categories That May Benefit Most

Once the above steps are completed, we can identify specific patient categories for whom buprenorphine for chronic pain is an excellent consideration.

• Patients with Inadequate Analgesia Post-Opioids: Individuals who were previously on full-agonist opioids, have since tapered off, and now find non-opioid options insufficient.
• Patients at High Risk from Full-Agonist Opioids: This includes elderly patients, those with sleep apnea, kidney or liver issues, or a personal/family history of substance use disorder.
• Patients Struggling with an Opioid Taper: A patient on a stable dose of a full-agonist opioid who is experiencing unbearable pain or withdrawal while attempting to taper. Rotating to buprenorphine can provide a safer, more stable platform for analgesia.

Choosing the Right Buprenorphine Formulation: A Clinical Guide

The choice of formulation depends primarily on the patient’s prior opioid exposure, which we quantify using Morphine Milligram Equivalents (MME) per day.

1. For patients taking less than 100 MME per day, the pain-specific formulations—the transdermal patch (Butrans) or the buccal film (Belbuca)—are likely to be excellent options.
2. For patients on very high doses (greater than 100 MME per day), or if they have a concurrent diagnosis of OUD, we would go straight to the sublingual buprenorphine formulations (off-label for pain). The transdermal and buccal doses are unlikely to be strong enough to manage their pain and prevent withdrawal at those high MME levels.

A Deep Dive into Buprenorphine Transdermal Patch (Butrans) Therapy

The Butrans transdermal patch is an excellent starting point for many patients, providing steady, round-the-clock pain relief.

• Initiating Butrans: For patients on full-agonists, the ideal protocol involves tapering their dose to less than 30 MME per day before switching. For opioid-naive patients (or <30 MME/day), the starting dose is 5 micrograms (mcg) per hour. For those on 30-80 MME/day, the starting dose is 10 mcg per hour. Patients over 80 MME/day are generally not good candidates for Butrans alone.
• Titration and Breakthrough Pain: After 72 hours, the dose can be increased gradually until pain is controlled or the max dose of 20 mcg per hour is reached. Short-acting analgesics (non-opioid or opioid) may be needed for breakthrough pain during titration.
• Clinical Pearls for Butrans:

• • Wear each patch for 7 days.
  • Rotate application sites each week (upper outer arm, upper chest, upper back, or side of chest).
  • Do not abruptly discontinue; taper gradually under medical supervision.
  • Avoid direct heat on the patch (heating pads, saunas) to prevent rapid absorption and potential overdose.

Understanding the Buprenorphine Buccal Film (Belbuca)

When a higher dose is needed, the buprenorphine buccal film, or Belbuca, is an excellent next option. It has much higher bioavailability (46-65%) than the patch (~15%).

• Dosing and Titration: Starting dose is based on prior MME: 75 mcg (for <30 MME), 150 mcg (for 30-89 MME), or 300 mcg (for >90 MME), usually every 12 hours. The dose can be titrated every four days upwards until pain is controlled, up to a maximum of 900 mcg every 12 hours.
• Stepped Approach: My general approach is to start low and go slow. I would likely begin with the Butrans patch and, if pain is not controlled at max dose, then transition to Belbuca.

Off-Label Use of Sublingual Buprenorphine for Complex Pain

For patients with very high-tolerance complex pain (e.g., history of >160 MME/day) who fail other formulations, we can consider an off-label use of sublingual buprenorphine (e.g., Suboxone, Subutex). This requires specialized knowledge and careful documentation of the clinical rationale.

Other Practical Considerations and Patient Counseling

• Side Effects: Nausea, headache, and constipation can occur but are often less severe than with full agonists.
• Time to Effect: The full analgesic effect can take up to two weeks to achieve. Patience is key.
• Insurance and Cost: These formulations can be costly and may require prior authorization. Our clinic assists with this process.

The Integrative Approach at Injury Medical Clinic: Where Chiropractic and Medical Care Converge

At our clinic, we don’t view conditions like chronic pain or the recovery from OUD through a single lens. We see a whole person whose neuro-musculoskeletal system is intricately linked with their neurochemical and psychological state. This is where our collaborative model, integrating the expertise of Dr. Maria Cardenas, MD, with my background in chiropractic and functional medicine, becomes so powerful.

The Role of Chiropractic Care in Pain and Recovery

When a patient is struggling with chronic pain, whether or not it is complicated by opioid dependence, their body is often in a state of sustained physical stress. This can manifest as:

• Myofascial Pain Syndromes: Persistent pain can lead to tight, painful trigger points in muscles and fascia.
• Spinal Misalignments (Subluxations): Poor posture, guarding movements, and muscle imbalances can cause vertebral segments to lose their normal motion, irritating surrounding nerves and soft tissues.
• Nerve Entrapment and Irritation: Misaligned spinal structures or inflamed soft tissues can compress or irritate nerves, leading to radiating pain, numbness, or weakness. This is the physiological basis of conditions like sciatica.
• Altered Biomechanics: The body compensates for pain by changing movement patterns, which can strain other joints and muscles and create new sources of pain.

My role as a chiropractor is to identify and address these biomechanical and structural dysfunctions. Through specific chiropractic adjustments, we can:

1. Restore Joint Mobility: Gentle, precise adjustments help restore normal motion to restricted spinal and extremity joints, relieving stiffness and improving function.
2. Reduce Nerve Irritation: By correcting misalignments, we can alleviate pressure on spinal nerves, which can significantly reduce pain and improve nerve signaling.
3. Decrease Muscle Tension: Adjustments can have a reflex effect on surrounding muscles, helping to reduce hypertonicity and alleviate the pain associated with muscle spasms.
4. Improve Proprioception: Chiropractic care enhances the body’s awareness of its position in space (proprioception). This improved communication between the body and the brain can lead to better coordination, balance, and more efficient movement patterns, breaking the cycle of compensatory strain.

Integrating Chiropractic with Medical and Functional Medicine

While I address the structural “hardware” of the body, Dr. Cardenas provides essential medical oversight for the “software”—the patient’s neurochemistry and systemic health. When a patient is on a medication like buprenorphine for chronic pain or OUD, Dr. Cardenas manages the prescription, monitors for side effects, and ensures the medical appropriateness of the treatment plan.

This collaboration is seamless. For example, a patient with chronic low back pain and a history of opioid dependence might be started on buprenorphine under Dr. Cardenas’s care to manage their pain safely and effectively. Simultaneously, I would perform a thorough musculoskeletal evaluation and begin a course of chiropractic adjustments to address underlying sacroiliac joint dysfunction and lumbar facet restrictions. We might also incorporate:

• Soft Tissue Therapies: Techniques like myofascial release, trigger point therapy, and therapeutic massage to address muscular components of the pain.
• Rehabilitative Exercises: A tailored program of stretching and strengthening exercises to stabilize the spine, improve core strength, and prevent re-injury.
• Functional Medicine Principles: We would investigate potential drivers of systemic inflammation through dietary analysis and lab testing, recommending anti-inflammatory nutritional strategies and targeted supplementation to support tissue healing from the inside out.

This integrative model allows us to attack the problem from multiple angles. Buprenorphine provides a stable foundation of pain relief, creating a therapeutic window that allows the patient to tolerate and benefit more fully from chiropractic and rehabilitative therapies. As their structural function and biomechanics improve, their reliance on medication may decrease over time. This holistic, synergistic approach is the essence of true patient-centered care.

Integrating Chiropractic into Shared Decision-Making for OUD

In our practice, this is where the integrative model truly shines. As a chiropractor, I am trained to view the body as an interconnected system. The anxiety and restlessness of withdrawal are not just psychological phenomena; they are manifestations of a nervous system in a state of extreme dysregulation—a massive sympathetic (“fight or flight”) overdrive.

• Chiropractic Care During Induction: Gentle spinal adjustments and manual therapies can help modulate the autonomic nervous system, potentially easing physical tension, restlessness, and “body anxiety” associated with withdrawal. By promoting a parasympathetic (“rest and digest”) response, we can support the body’s intrinsic ability to find balance, even amidst the turmoil of a medication transition. This becomes a powerful, non-pharmacological tool to complement the medical treatment.
• Functional Medicine Lens: A functional medicine lens prompts us to ask why this individual might be more susceptible to severe withdrawal. We look at underlying factors like adrenal health (the HPA axis), neurotransmitter balance, and nutritional status. For example, supporting the adrenal glands with adaptogenic herbs or ensuring adequate magnesium levels can have a significant impact on managing anxiety and muscle cramps. This approach allows us to personalize supportive care around the core buprenorphine initiation protocol.

Under the medical direction of Dr. Cardenas, we ensure these integrative therapies are safe and appropriate, never interfering with the primary medical treatment but enhancing the patient’s overall resilience and comfort.

Harm Reduction: A Compassionate and Evidence-Based Approach

A vital philosophy that guides our approach not only to treating substance use disorder but also to ensuring the safety of all patients who use substances, whether prescribed or illicit, is harm reduction.

What is Harm Reduction?

Harm reduction is an evidence-based, public health approach. It is a set of practical strategies and ideas aimed at reducing the negative consequences associated with substance use. It is built on a foundation of respect and compassion.

• It values people as experts in their own experiences. We listen without judgment.
• It acknowledges the reality that many people are not able or not willing to abstain from drug use at a given point in time.
• It asserts that abstinence should not be a precondition for receiving help, dignity, and life-saving care.

Key Harm Reduction Messages for Patient Conversations

When talking to any patient about opioid use, the conversation is not about judgment; it is about safety. Here are some key messages.

1. Assume Illicit Substances Contain Fentanyl: The illicit drug supply is dangerously altered. “It is very likely that any pill, powder, or substance you buy off the street, even if it looks like an oxycodone or Xanax pill, contains fentanyl.” This means there is a very high risk of overdose.
2. The Critical Importance of Naloxone (Narcan): Naloxone is an opioid overdose reversal medication. I tell my patients, “Carry Narcan like you would your phone or your keys.” I make it a standard practice to prescribe naloxone whenever possible to all of my patients with OUD and also to patients who are on full-agonist opioids for chronic pain.
3. Safer Methods of Use: While no illicit drug use is “safe,” some methods carry a lower risk than others.

• • “Smoking fentanyl carries a lower risk of overdose and transmission of infectious disease than injecting it.” This is not an endorsement, but a comparison of relative harms. Smoking eliminates the significant risks of blood-borne infections that come with non-sterile injection.
  • If a patient is going to inject, we must talk about safe injection techniques: clean skin and hands, use purified water, and never share equipment.

These conversations acknowledge reality and do everything in our power to keep people alive and as healthy as possible until they are ready and able to make different choices. Harm reduction is healthcare.

Conclusion: The Art and Science of Personalized Care

The journey to recovery from Opioid Use Disorder and chronic pain is deeply personal. The rise of fentanyl has forced us to abandon rigid, outdated protocols and embrace a new paradigm of flexible, individualized, and patient-centered care. No single method is “best.” The low-dose approach offers a gentle transition ideal for anxious patients, while the high-dose approach provides a rapid solution for acute care, but both have trade-offs. The emergence of buprenorphine as a therapeutic option for pain also represents a significant step forward, offering effective analgesia with a greater margin of safety.

At Injury Medical Clinic, our strength lies in our ability to navigate these options collaboratively. Under the expert medical direction of Dr. Maria Guadalupe Cardenas, MD, we can safely prescribe and manage these complex protocols. My own background in chiropractic and functional medicine allows us to wrap a layer of holistic support around this medical foundation. We use chiropractic adjustments to help calm the overwrought nervous system, nutritional strategies to replete depleted resources, and a deep commitment to shared decision-making to honor thepatient’ss own wisdom and priorities.

By integrating these diverse fields, we are not just treating a disorder; we are caring for a whole person. We are building a partnership based on trust, knowledge, and compassion, empowering our patients in El Paso, Texas, to take that brave first step toward a new life. The path may be challenging, but with the right tools, the right team, and the right philosophy, recovery is always possible.

References

• American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.).
• American Society of Addiction Medicine. (2023). Appropriate use of drug testing in clinical addiction medicine. ASAM.
• Dowell, D., Ragan, K. R., Jones, C. M., & Chou, R. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. Recommendations and Reports, 71(No. RR-3), 1–95.
• Kampman, K., & Jarvis, M. (2015). American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Journal of Addiction Medicine, 9(5), 358–367.
• King, R. S., Ghaffari, K., Korthuis, P. T., & Priest, K. C. (2023). Qualitative analysis of patient preferences for buprenorphine initiation. Journal of Addiction Medicine, 17(5), 527-532.
• Kruger, D. J., & RYN, A. (2019). The synergy of medicine and chiropractic: A case study of a multidisciplinary clinic. Journal of Multidisciplinary Healthcare, 12, 97-103.
• Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, (2), CD002207.
• Pergolizzi, J. V., Jr., Raffa, R. B., & LeQuang, J. A. (2019). The role of buprenorphine in the management of chronic pain. Pain Management, 9(4), 363-376.
• Priest, K. C., & Korthuis, P. T. (2023). Buprenorphine initiation strategies for the fentanyl era. Journal of Addiction Medicine, 17(5), 499-501.
• (2020). Harm Reduction. Substance Abuse and Mental Health Services Administration.
• Schuckit, M. A. (2016). Treatment of Opioid-Use Disorders. The New England Journal of Medicine, 375(4), 357–368.
• Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology & Therapeutics, 55(5), 569–580.
• Webster, L. R. (2017). A review of the science and safety of buprenorphine for chronic pain. Pain Medicine, 18(suppl_1), S1-S3.

SEO Tags: Buprenorphine, Opioid Use Disorder, Chronic Pain Management, Fentanyl, Precipitated Withdrawal, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, Integrative Chiropractic Care, El Paso Chiropractor, Functional Medicine, Methadone, Naltrexone, Suboxone, Medication-Assisted Treatment, Pain Management, Buprenorphine Initiation, Low-Dose Buprenorphine, Microdosing, High-Dose Buprenorphine, Shared Decision-Making, Harm Reduction, Naloxone, Butrans patch, Belbuca buccal film, Chiropractic Adjustment, Spinal Health, Personal Injury Care, Rehabilitation, Neuromusculoskeletal Health, El Paso TX, Addiction Treatment, COWS Scale, Adjunct Medications